New drug combo aims to control Hard-to-Treat prostate cancer

NCT ID NCT07206056

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of two drugs (tulmimetostat and JSB462) in men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then comparing the combination to usual care in 188 participants. The goal is to see if the combo can shrink tumors or lower PSA levels better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Cleveland Clinic Foundation
RECRUITING

Cleveland, Ohio, 44195, United States
Emory University
RECRUITING

Atlanta, Georgia, 30329, United States
Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109-1024, United States
Mass General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Novartis Investigative Site
RECRUITING

St Leonards, New South Wales, 2065, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site
RECRUITING

Liverpool, 2170, Australia
Novartis Investigative Site
RECRUITING

Halifax, Nova Scotia, B3H 2Y9, Canada
Novartis Investigative Site
RECRUITING

Beijing, 100021, China
Novartis Investigative Site
RECRUITING

Herlev, DK-2730, Denmark
Novartis Investigative Site
RECRUITING

Odense C, 5000, Denmark
Novartis Investigative Site
RECRUITING

Vejle, DK-7100, Denmark
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Paris, 75015, France
Novartis Investigative Site
RECRUITING

Paris, 75231, France
Novartis Investigative Site
RECRUITING

Düsseldorf, North Rhine-Westphalia, 40225, Germany
Novartis Investigative Site
RECRUITING

Milan, MI, 20133, Italy
Novartis Investigative Site
RECRUITING

Padova, PD, 35128, Italy
Novartis Investigative Site
RECRUITING

Orbassano, TO, 10043, Italy
Novartis Investigative Site
RECRUITING

Kuching, Sarawak, 93586, Malaysia
Novartis Investigative Site
RECRUITING

Tlalpan, Mexico City, 14050, Mexico
Novartis Investigative Site
RECRUITING

Poznan, 60-192, Poland
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore
Novartis Investigative Site
RECRUITING

Singapore, S308433, Singapore
Novartis Investigative Site
RECRUITING

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site
RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28009, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28041, Spain
Novartis Investigative Site
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom
Novartis Investigative Site
RECRUITING

London, W1G 6AD, United Kingdom
Sarah Cannon Research Institute
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute
RECRUITING

Jacksonville, Florida, 32256, United States
Wichita Urology Group PA
RECRUITING

Wichita, Kansas, 67226, United States